Acitretin
- Generic Name
- Acitretin
- Brand Names
- Soriatane
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O3
- CAS Number
- 55079-83-9
- Unique Ingredient Identifier
- LCH760E9T7
- Background
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
- Indication
For the treatment of severe psoriasis in adults.
- Associated Conditions
- Keratinization disorders, Severe Psoriasis
Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 61
- Registration Number
- NCT01039142
- Locations
- 🇮🇳
Post Graduate institute Of Medical Education and Research, Chandigarh, India
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00936065
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Stiefel, a GSK Company
- Registration Number
- NCT00832364
- Locations
- 🇺🇸
UCSF - Dermatology Psoriasis & Skin Treatment Center, San Francisco, California, United States
🇺🇸Mt. Sinai School of Medicine Department of Dermatology, New York, New York, United States
🇺🇸Physicians Skin Care, Louisville, Kentucky, United States
Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- Istituti Fisioterapici Ospitalieri
- Target Recruit Count
- 36
- Registration Number
- NCT00723437
- Locations
- 🇮🇹
Department of Dermatology University of Bologna, Bologna, Italy
Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer
- Conditions
- Non-melanomatous Skin Cancer
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 130
- Registration Number
- NCT00644384
Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 40
- Registration Number
- NCT00395941
- Locations
- 🇮🇳
PGIMER, Chandigarh, India
Acitretin and Etanercept in Psoriasis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-02-16
- Target Recruit Count
- 10
- Registration Number
- NCT00156247
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
- Conditions
- Non-melanomatous Skin Cancer
- Interventions
- Other: placebo
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 129
- Registration Number
- NCT00003611
- Locations
- 🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸CCOP - Wichita, Wichita, Kansas, United States
🇺🇸CCOP - Carle Cancer Center, Urbana, Illinois, United States
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
- Conditions
- HIV InfectionsPsoriasis
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00002143
- Locations
- 🇺🇸
Beth Israel Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.